2023 Volume 12 Issue 1 Pages 43-47
CAR-T cell therapy was approved as a standard treatment for relapsed/refractory B-cell acute lymphoblastic leukemia and diffuse large B-cell lymphoma in May 2019. CAR-T cell therapy is one of the cancer immunotherapies, and autologous T cells are genetically modified so as to specifically attack the target tumor cells. Specific adverse events including the “on target, off tumor” effect, cytokine release syndrome, and neurological symptoms are reported; therefore the thorough safely management system is required. Nurses are required to detect and report these abnormalities at the earliest timing, to educate patients, and to provide safe and secured medical care to patients and their families undergoing CAR-T cell therapy.
